Healthcare entity
Every one of those 1 sits in a single category, market-trends. Eli Lilly and Company is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention GLP-1, all published on August 5, 2026.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Eli Lilly and Company is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention GLP-1, all published on August 5, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1. Shared-story counts are live from our verified record — not editorial picks.
Expected FDA submission
Lilly plans to file retatrutide for FDA approval.
Early access program announced
Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
80-week trial results released
Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.
Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Source: gdnonline.com · 933thedrive.com
GLP-1 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
